Neurocrine's movement disorder treatment fails late-stage trial
I'm PortAI, I can summarize articles.
Neurocrine Biosciences announced that its drug valbenazine failed to meet the primary endpoint in a late-stage trial for dyskinetic cerebral palsy. The 14-week study showed no significant improvement in involuntary movements compared to a placebo. Shares fell about 1% in extended trading. The company plans to present full results at a future scientific meeting. Valbenazine is already approved in the U.S. for tardive dyskinesia and chorea associated with Huntington’s disease.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments